Innovent Biologics, Inc. Sets 360 μg/kg RP2D After Phase 1 IBI3003 Update
Innovent reported updated Phase 1 data for trispecific antibody IBI3003 in R/R multiple myeloma and set a 360 μg/kg RP2D, citing rapid, deep responses and a manageable safety profile; Phase 3 TriadicMM-1 in China is ongoing.Material DetailsContext by AI AnalystThis is mid-stage clinical validation…